Shares of ImmuPharma plc (LON:IMM – Get Free Report) dropped 9.4% during trading on Thursday . The stock traded as low as GBX 3.50 and last traded at GBX 3.54. 1,941,681 shares traded hands during mid-day trading, a decline of 22% from the average daily volume of 2,487,819 shares. The stock had previously closed at GBX 3.90.
ImmuPharma Price Performance
The stock has a market capitalization of £22.06 million, a price-to-earnings ratio of -9.55 and a beta of 3.01. The firm has a fifty day moving average of GBX 3.89 and a 200 day moving average of GBX 4.62.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
- Chewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for Investors
- Insider Sales Eclipse $450M Across 3 AI Winners, With NVIDIA Leading the Pack
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
